Extended Data Table 1 Subsequent treatment in all patients who underwent randomizationa

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

  1. aPatients may have received more than one type of post-protocol therapy, and more than one agent within each type. All percentages are based on the total number of patients in each arm. CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed death-1.
Back to article page